RNAC · Insider Trading
Cartesian Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by RNAC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | Murat Kalayoglu | 10%+ Owner | M | +758,001 | — |
| 2026-04-06 | Seven One Eight Three Four Irrevocable Trust | 10%+ Owner | M | +1,516,002 | — |
| 2026-03-13 | Michael Singer | Director | G | −6,555 | — |
| 2026-01-08 | Milos Miljkovic | Chief Medical Officer | Sell | −3,573 | −$24.37K |
| 2026-01-08 | Carsten Brunn | President and CEO | Sell | −23,766 | −$162.08K |
| 2026-01-08 | Blaine Davis | Chief Financial Officer | Sell | −10,591 | −$72.23K |
| 2026-01-06 | June Ann Seymour | Chief Accounting Officer | A | +6,500 | — |
| 2026-01-06 | Emily English | Chief Operations Officer | A | +24,000 | — |
| 2026-01-06 | Blaine Davis | Chief Financial Officer | A | +37,000 | — |
| 2026-01-06 | Kemal Malik | Director | A | +2,600 | — |
| 2026-01-06 | Timothy C Barabe | Director | A | +2,600 | — |
| 2026-01-06 | Carsten Brunn | President and CEO | A | +143,200 | — |
| 2026-01-06 | Nishan M DeSilva | Director | A | +2,600 | — |
| 2026-01-06 | Milos Miljkovic | Chief Medical Officer | A | +27,000 | — |
| 2026-01-06 | Patrick J Zenner | Director | A | +2,600 | — |
| 2026-01-06 | Murat Kalayoglu | Director | A | +2,600 | — |
| 2026-01-06 | Timothy A Springer | Director | A | +2,600 | — |
| 2026-01-06 | Michael Singer | Director | A | +2,600 | — |
| 2026-01-02 | Emily English | Chief Operations Officer | M | +7,500 | +$24.75K |
| 2025-12-18 | Adrian Ion Bot | Director | A | +5,800 | — |
| 2025-12-08 | Timothy C Barabe | Director | Buy | +30,000 | +$205.80K |
| 2025-12-02 | Emily English | Chief Operations Officer | M | +7,500 | +$24.75K |
| 2025-11-19 | Michael Singer | Director | G | −20,000 | — |
| 2025-10-28 | June Ann Seymour | Chief Accounting Officer | A | +50,000 deriv. | — |
| 2025-05-14 | Emily English | Chief Operations Officer | M | +7,500 | +$24.75K |
| 2025-04-16 | Emily English | Chief Operations Officer | M | +7,500 | +$24.75K |
| 2025-04-11 | Timothy A Springer | Director | Buy | +149,075 | +$1.52M |
| 2025-03-20 | Timothy A Springer | Director | Buy | +89,863 | +$1.37M |
| 2025-01-15 | Timothy A Springer | Director | Buy | +20,967 | +$366.35K |
| 2025-01-13 | Christopher M Jewell | Chief Scientific Officer | M | +9,000 | +$29.07K |
| 2025-01-07 | Blaine Davis | Chief Financial Officer | Sell | −7,989 | −$134.04K |
| 2025-01-07 | Milos Miljkovic | Chief Medical Officer | Sell | −1,880 | −$31.54K |
| 2025-01-07 | Emily English | Chief Operations Officer | Sell | −1,797 | −$30.15K |
| 2025-01-07 | Christopher M Jewell | Chief Scientific Officer | Sell | −2,550 | −$42.78K |
| 2025-01-07 | Metin Kurtoglu | Chief Technology Officer | Sell | −4,875 | −$81.79K |
| 2025-01-07 | Carsten Brunn | President and CEO | Sell | −17,271 | −$289.76K |
| 2025-01-06 | Nishan M DeSilva | Director | A | +2,600 | — |
| 2025-01-06 | Timothy A Springer | Director | A | +2,600 | — |
| 2025-01-06 | Milos Miljkovic | Chief Medical Officer | A | +19,000 | — |
| 2025-01-06 | Timothy C Barabe | Director | A | +2,600 | — |
| 2025-01-06 | Christopher M Jewell | Chief Scientific Officer | A | +16,100 | — |
| 2025-01-06 | Murat Kalayoglu | Director | A | +2,600 | — |
| 2025-01-06 | Kemal Malik | Director | A | +2,600 | — |
| 2025-01-06 | Emily English | Chief Operations Officer | A | +16,100 | — |
| 2025-01-06 | Carsten Brunn | President and CEO | A | +57,500 | — |
| 2025-01-06 | Blaine Davis | Chief Financial Officer | A | +22,000 | — |
| 2025-01-06 | Patrick J Zenner | Director | A | +2,600 | — |
| 2025-01-06 | Carrie Smith Cox | Director | A | +2,600 | — |
| 2025-01-06 | Michael Singer | Director | A | +2,600 | — |
| 2025-01-06 | Metin Kurtoglu | Chief Technology Officer | A | +16,100 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Timothy A Springer | Director | 9,302,798 | $59.72M |
| Murat Kalayoglu | Director | 5,820,260 | $37.37M |
| Seven One Eight Three Four Irrevocable Trust | 10%+ Owner | 506,999 | $3.25M |
| Carsten Brunn | President and CEO | 323,530 | $2.08M |
| Michael Singer | Director | 145,797 | $936.02K |
| Blaine Davis | Chief Financial Officer | 121,220 | $778.23K |
| Emily English | Chief Operations Officer | 94,226 | $604.93K |
| Christopher M Jewell | Chief Scientific Officer | 62,490 | $401.19K |
| Metin Kurtoglu | Chief Technology Officer | 62,258 | $399.70K |
| Milos Miljkovic | Chief Medical Officer | 58,820 | $377.62K |
| Timothy C Barabe | Director | 56,966 | $365.72K |
| Carrie Smith Cox | Director | 15,629 | $100.34K |
| Patrick J Zenner | Director | 12,974 | $83.29K |
| Nishan M DeSilva | Director | 11,366 | $72.97K |
| Kemal Malik | Director | 11,133 | $71.47K |
| June Ann Seymour | Chief Accounting Officer | 6,500 | $41.73K |
| Adrian Ion Bot | Director | 5,800 | $37.24K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RNAC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.